Bicycle Therapeutics PLC (BCYC) has a current Price-to-Book (P/B) ratio of 0.75. Compared to its 3-year average P/B ratio of 1.81, the current P/B ratio is approximately -58.61% higher. Relative to its 5-year average P/B ratio of 2.83, the current P/B ratio is about -73.52% higher. Bicycle Therapeutics PLC (BCYC) has a Forward Free Cash Flow (FCF) yield of approximately -52.20%. Compared to its 3-year average FCF yield of -19.20%, the current FCF yield is approximately 171.80% lower. Relative to its 5-year average FCF yield of -13.88%, the current FCF yield is about 276.17% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BCYC competitors is 7.47, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC.O) exhibits a P/S ratio of 16.73, which is 124.08% above the industry average. Given its robust revenue growth of 338.49%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BCYC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BCYC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BCYC currently overvalued or undervalued?

What is Bicycle Therapeutics PLC (BCYC) fair value?

BCYC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bicycle Therapeutics PLC (BCYC) is between 4.99 to 19.07 according to relative valuation method.

How does BCYC's valuation metrics compare to the industry average?

The average P/S ratio for BCYC's competitors is 7.47, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC) exhibits a P/S ratio of 16.73, which is 124.08% above the industry average. Given its robust revenue growth of 338.49%, this premium appears sustainable.

What is the current P/B ratio for Bicycle Therapeutics PLC (BCYC) as of Mar 02 2026?

As of Mar 02 2026, Bicycle Therapeutics PLC (BCYC) has a P/B ratio of 0.75. This indicates that the market values BCYC at 0.75 times its book value.

What is the current FCF Yield for Bicycle Therapeutics PLC (BCYC) as of Mar 02 2026?

As of Mar 02 2026, Bicycle Therapeutics PLC (BCYC) has a FCF Yield of -52.20%. This means that for every dollar of Bicycle Therapeutics PLC's market capitalization, the company generates -52.20 cents in free cash flow.

What is the current Forward P/E ratio for Bicycle Therapeutics PLC (BCYC) as of Mar 02 2026?

As of Mar 02 2026, Bicycle Therapeutics PLC (BCYC) has a Forward P/E ratio of -1.94. This means the market is willing to pay $-1.94 for every dollar of Bicycle Therapeutics PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bicycle Therapeutics PLC (BCYC) as of Mar 02 2026?

As of Mar 02 2026, Bicycle Therapeutics PLC (BCYC) has a Forward P/S ratio of 16.73. This means the market is valuing BCYC at $16.73 for every dollar of expected revenue over the next 12 months.

BCYC Valuation